Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy

Author(s): Feride Pınar Altay*, Aydan Farzaliyeva, Özlem Turhan İyidir, Yusuf Bozkuş, Nazlı Gülsoy Kırnap, Altuğ Kut, Aslı Nar and Neslihan Başçıl Tütüncü

Volume 23, Issue 6, 2023

Published on: 06 January, 2023

Page: [826 - 831] Pages: 6

DOI: 10.2174/1871530323666221124112413

Price: $65

Abstract

Aim: A co-formulation containing insulin degludec and insulin aspart (IDegAsp) is available for the treatment of diabetes in Turkey. We aimed to evaluate the clinical results of switching to IDegAsp treatment for Type 2 diabetes.

Methods: A total of 217 patients with type 2 diabetes treated with IDegAsp and having follow-up data were included. The patients were divided into 3 groups. Group 1 switched from basal insulin to IDegAsp, group 2 switched from twice-daily premixed insulin regimen to IDegAsp, and group 3 switched from intensive and thrice-daily premixed insulin regimen to IDegAsp. Groups were evaluated in terms of changes in insulin dose, the number of injections, and changes in HbA1c.

Results: The mean follow-up period was 7.5 ± 4.4 months. The mean age was 62.8 ± 12.9 years. The mean duration of diabetes was 15.3 ± 8 years. There was a significant decrease in HbA1c and glucose (p < 0.0001 and p < 0.0001, respectively). HbA1c was significantly reduced in group 1 (p < 0.0001) while insulin dose and the number of injections increased (p < 0.0001 and p < 0.0001, respectively). HbA1c, insulin dose, and the number of injections in group 2 and group 3 (p = 0.001, p = 0.002, p < 0.0001, respectively, and p < 0.0001, p = 0.043, p < 0.0001, respectively) were significantly reduced.

Conclusion: This study includes real-life experiences involving a remarkable number of patients in the literature. IDegAsp treatment provided effective blood glucose regulation and caused a significant decrease in the insulin dose and the number of injections, resulting in increased quality of life among those who had to receive twice or more insulin injections.

« Previous Next »
Graphical Abstract

[1]
International Diabetes Federation. Available from: https://idf.org (Accessed September 24, 2021).
[2]
Bolli, G.B.; Riddle, M.C.; Bergenstal, R.M.; Ziemen, M.; Sestakauskas, K.; Goyeau, H.; Home, P.D. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab., 2015, 17(4), 386-394.
[http://dx.doi.org/10.1111/dom.12438] [PMID: 25641260]
[3]
Terauchi, Y.; Koyama, M.; Cheng, X.; Takahashi, Y.; Riddle, M.C.; Bolli, G.B.; Hirose, T. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes. Metab., 2016, 18(4), 366-374.
[http://dx.doi.org/10.1111/dom.12618] [PMID: 26662838]
[4]
Yki-Järvinen, H.; Bergenstal, R.M.; Bolli, G.B.; Ziemen, M.; Wardecki, M.; Muehlen-Bartmer, I.; Maroccia, M.; Riddle, M.C. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension. Diabetes Obes. Metab., 2015, 17(12), 1142-1149.
[http://dx.doi.org/10.1111/dom.12532] [PMID: 26172084]
[5]
Marso, S.P.; McGuire, D.K.; Zinman, B.; Poulter, N.R.; Emerson, S.S.; Pieber, T.R.; Pratley, R.E.; Haahr, P.M.; Lange, M.; Brown-Frandsen, K.; Moses, A.; Skibsted, S.; Kvist, K.; Buse, J.B. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med., 2017, 377(8), 723-732.
[http://dx.doi.org/10.1056/NEJMoa1615692] [PMID: 28605603]
[6]
Rodbard, H.W.; Cariou, B.; Zinman, B.; Handelsman, Y.; Philis-Tsimikas, A.; Skjøth, T.V.; Rana, A.; Mathieu, C. Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial. Diabet. Med., 2013, 30(11), 1298-1304.
[http://dx.doi.org/10.1111/dme.12303] [PMID: 23952326]
[7]
Wysham, C.; Bhargava, A.; Chaykin, L.; de la Rosa, R.; Handelsman, Y.; Troelsen, L.N.; Kvist, K.; Norwood, P. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA, 2017, 318(1), 45-56.
[http://dx.doi.org/10.1001/jama.2017.7117] [PMID: 28672317]
[8]
Zinman, B.; Philis-Tsimikas, A.; Cariou, B.; Handelsman, Y.; Rodbard, H.W.; Johansen, T.; Endahl, L.; Mathieu, C. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care, 2012, 35(12), 2464-2471.
[http://dx.doi.org/10.2337/dc12-1205] [PMID: 23043166]
[9]
Lipska, K.J.; Parker, M.M.; Moffet, H.H.; Huang, E.S.; Karter, A.J. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA, 2018, 320(1), 53-62.
[http://dx.doi.org/10.1001/jama.2018.7993] [PMID: 29936529]
[10]
Heise, T.; Tack, C.J.; Cuddihy, R.; Davidson, J.; Gouet, D.; Liebl, A.; Romero, E.; Mersebach, H.; Dykiel, P.; Jorde, R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care, 2011, 34(3), 669-674.
[http://dx.doi.org/10.2337/dc10-1905] [PMID: 21285389]
[11]
Onishi, Y.; Ono, Y.; Rabøl, R.; Endahl, L.; Nakamura, S. Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes. Metab., 2013, 15(9), 826-832.
[http://dx.doi.org/10.1111/dom.12097] [PMID: 23557077]
[12]
Liebl, A.; Davidson, J.; Mersebach, H.; Dykiel, P.; Tack, C.J.; Heise, T. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J. Diabetes Sci. Technol., 2013, 7(5), 1328-1336.
[http://dx.doi.org/10.1177/193229681300700524] [PMID: 24124961]
[13]
Niskanen, L.; Leiter, L.A.; Franek, E.; Weng, J.; Damci, T.; Muñoz-Torres, M.; Donnet, J.P.; Endahl, L.; Skjøth, T.V.; Vaag, A. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur. J. Endocrinol., 2012, 167(2), 287-294.
[http://dx.doi.org/10.1530/EJE-12-0293] [PMID: 22660026]
[14]
Fulcher, G.R.; Christiansen, J.S.; Bantwal, G.; Polaszewska-Muszynska, M.; Mersebach, H.; Andersen, T.H.; Niskanen, L.K. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care, 2014, 37(8), 2084-2090.
[http://dx.doi.org/10.2337/dc13-2908] [PMID: 24812432]
[15]
Kaneko, S.; Chow, F.; Choi, D.S.; Taneda, S.; Hirao, K.; Park, Y.; Andersen, T.H.; Gall, M.A.; Christiansen, J.S. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial. Diabetes Res. Clin. Pract., 2015, 107(1), 139-147.
[http://dx.doi.org/10.1016/j.diabres.2014.09.026] [PMID: 25498130]
[16]
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care, 2019, 42(S1), S90-S102.
[http://dx.doi.org/10.2337/dc19-S009] [PMID: 30559235]
[17]
Kisioglu, S.V.; Demir, A.S.; Tufekci, D.; Emur Gunay, Y.; Coskun, H.; Ucuncu, O.; Nuhoglu, I.; Kocak, M.; Karakullukcu, S.; Ersoz, H.O. Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience. Int. J. Clin. Pract., 2021, 75(9), e14377.
[http://dx.doi.org/10.1111/ijcp.14377] [PMID: 34003539]
[18]
Kalra, S.; Baruah, M. Insulin degludec aspart: One-year real world experience. Indian J. Endocrinol. Metab., 2016, 20(3), 369-371.
[http://dx.doi.org/10.4103/2230-8210.177416] [PMID: 27186556]
[19]
Haliloğlu, O.; Korkmaz, M.; Korkmaz, O.; Şahin, S.; Durcan, E.; Siva, Z. Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience. Annals. Med. Res., 2020, 27(7), 1961-1965.
[http://dx.doi.org/10.5455/annalsmedres.2020.04.363]
[20]
Özçelik, S.; Çelik, M.; Vural, A.; Aydın, B.; Özçelik, M.; Gozu, H. Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience. Arch. Med. Sci., 2021, 17(1), 1-8.
[http://dx.doi.org/10.5114/aoms.2020.93264] [PMID: 33488849]
[21]
Onder, C.; Kuşkonmaz, S.M.; Koc, G.; Firat, S.; Omma, T.; Taskaldiran, I.; Gokbulut, P.; Culha, C. Factors that affect the glycemic control achieved by switching to insulin degludec/aspart in insulin-treated patients with type 1 and type 2 diabetes in a real-world setting: a non-interventional, retrospective cohort study. Acta Endocrinol., 2020, 16(4), 443-448.
[http://dx.doi.org/10.4183/aeb.2020.443] [PMID: 34084235]
[22]
Fulcher, G.R.; Jarlov, H.; Piltoft, J.S.; Singh, K.P.; Liu, L.; Mohamed, M.; Nicodemus, N.A., Jr; Al-Jaser, S.J.; Kok, A. ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. Endocrine, 2021, 74(3), 530-537.
[http://dx.doi.org/10.1007/s12020-021-02887-8] [PMID: 34637072]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy